Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1988 Jun 4;296(6636):1554–1556. doi: 10.1136/bmj.296.6636.1554

Regular Review: Interferon for treatment: the dust settles

D Galvani, S D Griffiths, J C Cawley
PMCID: PMC2545949  PMID: 2456124

Full text

PDF
1554

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahre A., Björkholm M., Mellstedt H., Brenning G., Engstedt L., Gahrton G., Gyllenhammar H., Holm G., Johansson B., Järnmark M. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep. 1984 Nov;68(11):1331–1338. [PubMed] [Google Scholar]
  2. Billard C., Ferbus D., Kolb J. P., Rosa F., Perrot J. Y., Merlin G., Janiaud P., Raynaud N., Thang M. N., Fellous M. Qualitative differences in effects of recombinant alpha-, beta- and gamma-interferons on human peripheral blood leukocytes in vitro. Ann Inst Pasteur Immunol. 1986 May-Jun;137C(3):259–272. doi: 10.1016/s0771-050x(86)80045-6. [DOI] [PubMed] [Google Scholar]
  3. Broxmeyer H. E., Lu L., Platzer E., Feit C., Juliano L., Rubin B. Y. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol. 1983 Sep;131(3):1300–1305. [PubMed] [Google Scholar]
  4. Costanzi J. J., Cooper M. R., Scarffe J. H., Ozer H., Grubbs S. S., Ferraresi R. W., Pollard R. B., Spiegel R. J. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol. 1985 May;3(5):654–659. doi: 10.1200/JCO.1985.3.5.654. [DOI] [PubMed] [Google Scholar]
  5. De Maeyer-Guignard J., De Maeyer E. Immunomodulation by interferons: recent developments. Interferon. 1985;6:69–91. [PubMed] [Google Scholar]
  6. Dooley J. S., Davis G. L., Peters M., Waggoner J. G., Goodman Z., Hoofnagle J. H. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology. 1986 Jan;90(1):150–157. doi: 10.1016/0016-5085(86)90087-9. [DOI] [PubMed] [Google Scholar]
  7. Dorval T., Palangie T., Jouve M., Garcia-Giralt E., Israel L., Falcoff E., Schwab D., Pouillart P. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer. 1986 Jul 15;58(2):215–218. [PubMed] [Google Scholar]
  8. Douglas R. G., Jr The common cold--relief at last? N Engl J Med. 1986 Jan 9;314(2):114–115. doi: 10.1056/NEJM198601093140209. [DOI] [PubMed] [Google Scholar]
  9. Einat M., Resnitzky D., Kimchi A. Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature. 1985 Feb 14;313(6003):597–600. doi: 10.1038/313597a0. [DOI] [PubMed] [Google Scholar]
  10. Eriksson B., Oberg K., Alm G., Karlsson A., Lundqvist G., Andersson T., Wilander E., Wide L. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1986 Dec 6;2(8519):1307–1309. doi: 10.1016/s0140-6736(86)91435-2. [DOI] [PubMed] [Google Scholar]
  11. Ernstoff M. S., Kirkwood J. M. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med. 1984 Apr;76(4):593–596. doi: 10.1016/0002-9343(84)90282-1. [DOI] [PubMed] [Google Scholar]
  12. Eron L. J., Judson F., Tucker S., Prawer S., Mills J., Murphy K., Hickey M., Rogers M., Flannigan S., Hien N. Interferon therapy for condylomata acuminata. N Engl J Med. 1986 Oct 23;315(17):1059–1064. doi: 10.1056/NEJM198610233151704. [DOI] [PubMed] [Google Scholar]
  13. Foon K. A., Bottino G. C., Abrams P. G., Fer M. F., Longo D. L., Schoenberger C. S., Oldham R. K. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med. 1985 Feb;78(2):216–220. doi: 10.1016/0002-9343(85)90429-2. [DOI] [PubMed] [Google Scholar]
  14. Goldstein D., Laszlo J. Interferon therapy in cancer: from imaginon to interferon. Cancer Res. 1986 Sep;46(9):4315–4329. [PubMed] [Google Scholar]
  15. Golomb H. M. The treatment of hairy cell leukemia. Blood. 1987 Apr;69(4):979–983. [PubMed] [Google Scholar]
  16. Ikić D., Krusić J., Kirhmajer V., Knezević M., Maricić Z., Rode B., Jusić D., Soos E. Application of human leucocyte interferon in patients with carcinoma of the uterine cervix. Lancet. 1981 May 9;1(8228):1027–1030. doi: 10.1016/s0140-6736(81)92190-5. [DOI] [PubMed] [Google Scholar]
  17. Kimchi A. Increased levels of interferon-induced (2'--5') oligo-isoadenylate synthetase in mature T-lymphocytes and in differentiated Friend-erythroleukemic cells. J Interferon Res. 1981;1(4):559–569. doi: 10.1089/jir.1981.1.559. [DOI] [PubMed] [Google Scholar]
  18. Kirkwood J. M., Ernstoff M. S., Davis C. A., Reiss M., Ferraresi R., Rudnick S. A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul;103(1):32–36. doi: 10.7326/0003-4819-103-1-32. [DOI] [PubMed] [Google Scholar]
  19. Kurzrock R., Quesada J. R., Talpaz M., Hersh E. M., Reuben J. M., Sherwin S. A., Gutterman J. U. Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol. 1986 Jul;4(7):1101–1109. doi: 10.1200/JCO.1986.4.7.1101. [DOI] [PubMed] [Google Scholar]
  20. McCabe B. F., Clark K. F. Interferon and laryngeal papillomatosis. The Iowa experience. Ann Otol Rhinol Laryngol. 1983 Jan-Feb;92(1 Pt 1):2–7. doi: 10.1177/000348948309200102. [DOI] [PubMed] [Google Scholar]
  21. Merz B. Interferon's track record: good in hairy-cell leukemia, fair in other hematologic cancers, poor in solid tumors. JAMA. 1986 Sep 12;256(10):1242–1244. doi: 10.1001/jama.256.10.1242. [DOI] [PubMed] [Google Scholar]
  22. O'Connell M. J., Colgan J. P., Oken M. M., Ritts R. E., Jr, Kay N. E., Itri L. M. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1986 Feb;4(2):128–136. doi: 10.1200/JCO.1986.4.2.128. [DOI] [PubMed] [Google Scholar]
  23. Oberg K., Norheim I., Lind E., Alm G., Lundqvist G., Wide L., Jonsdottir B., Magnusson A., Wilander E. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep. 1986 Nov;70(11):1297–1304. [PubMed] [Google Scholar]
  24. Pestka S. Interferon: a decade of accomplishments, foundations of the future in research and therapy. Semin Hematol. 1986 Jul;23(3 Suppl 1):27–37. [PubMed] [Google Scholar]
  25. Quesada J. R., Hersh E. M., Manning J., Reuben J., Keating M., Schnipper E., Itri L., Gutterman J. U. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986 Aug;68(2):493–497. [PubMed] [Google Scholar]
  26. Quesada J. R., Reuben J., Manning J. T., Hersh E. M., Gutterman J. U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984 Jan 5;310(1):15–18. doi: 10.1056/NEJM198401053100104. [DOI] [PubMed] [Google Scholar]
  27. Quesada J. R., Talpaz M., Rios A., Kurzrock R., Gutterman J. U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 Feb;4(2):234–243. doi: 10.1200/JCO.1986.4.2.234. [DOI] [PubMed] [Google Scholar]
  28. Real F. X., Oettgen H. F., Krown S. E. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol. 1986 Apr;4(4):544–551. doi: 10.1200/JCO.1986.4.4.544. [DOI] [PubMed] [Google Scholar]
  29. Rubinstein M., Orchansky P. The interferon receptors. CRC Crit Rev Biochem. 1986;21(3):249–275. doi: 10.3109/10409238609113613. [DOI] [PubMed] [Google Scholar]
  30. Sherwin S. A., Knost J. A., Fein S., Abrams P. G., Foon K. A., Ochs J. J., Schoenberger C., Maluish A. E., Oldham R. K. A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA. 1982 Nov 19;248(19):2461–2466. [PubMed] [Google Scholar]
  31. Sreevalsan T., Rozengurt E., Taylor-Papadimitriou J., Burchell J. Differential effect of interferon on DNA synthesis, 2-deoxyglucose uptake and ornithine decarboxylase activity in 3T3 cells stimulated by polypeptide growth factors and tumor promotors. J Cell Physiol. 1980 Jul;104(1):1–9. doi: 10.1002/jcp.1041040102. [DOI] [PubMed] [Google Scholar]
  32. Strander H., Aparisi T., Blomgren H., Broström L. A., Cantell K., Einhorn S., Ingimarsson S., Nilsonne U., Söderberg G. Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Res. 1982;80:103–107. doi: 10.1007/978-3-642-81685-7_17. [DOI] [PubMed] [Google Scholar]
  33. Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986 Apr 24;314(17):1065–1069. doi: 10.1056/NEJM198604243141701. [DOI] [PubMed] [Google Scholar]
  34. Thomson B. J., Doran M., Lever A. M., Webster A. D. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet. 1987 Mar 7;1(8532):539–541. doi: 10.1016/s0140-6736(87)90178-4. [DOI] [PubMed] [Google Scholar]
  35. Vadhan-Raj S., Al-Katib A., Bhalla R., Pelus L., Nathan C. F., Sherwin S. A., Oettgen H. F., Krown S. E. Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol. 1986 Feb;4(2):137–146. doi: 10.1200/JCO.1986.4.2.137. [DOI] [PubMed] [Google Scholar]
  36. Worman C. P., Catovsky D., Bevan P. C., Camba L., Joyner M., Green P. J., Williams H. J., Bottomley J. M., Gordon-Smith E. C., Cawley J. C. Interferon is effective in hairy-cell leukaemia. Br J Haematol. 1985 Aug;60(4):759–763. doi: 10.1111/j.1365-2141.1985.tb07480.x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES